Members of the cdc25 family are protein phosphatases that play pivotal roles in cell cycle progression. Cdc25A has been shown to be a critical regulator of the G1/S transition of mammalian cells and to be a myc-target gene with oncongenic properties. We investigated the regulation of cdc25A during terminal dierentiation using myeloblastic leukemia M1 cells, that can be induced to undergo dierentiation into macrophages by interleukin-6 (IL-6) treatment. In this report it is shown that cdc25A protein is degraded by the ubiquitinproteasome machinery in both terminally dierentiating and cycling cells. Cdc25A was found to have two major peaks of accumulation during cell cycle progression, one in G1 and the other in S/G2. Evidence was obtained that degradation of cdc25A by the ubiquitin-proteasome machinery in terminally dierentiating myeloid cells is accelerated compared to cycling cells. Moreover, deregulated expression of c-myc in M1 cells, which had been previously shown to block terminal dierentiation, was also found to block IL-6 induced degradation of cdc25A. Oncogene (2000) 19, 2447 ± 2454.
Keywords: cdc25A; cell cycle; dierentiation; myc; proteasome; protein degradation; ubiquitin Cell cycle transitions of higher eukaryotic cells are regulated by distinct families of cyclin-dependent kinases (cdks). The activity of these kinases is controlled by association with other proteins, such as cyclins and cdk inhibitors, as well as by positive and negative phosphorylation events (Norbury and Nurse, 1992; Morgan, 1995; Roberts, 1995, Lew and Kornbluth, 1996) . Following association with cyclins and positive phosphorylation at a speci®c threonine residue, cdks are maintained in an inactive state by inhibitory phosphorylation at Thr-14 and Tyr-15 (reviewed in Morgan, 1995; Lew and Kornbluth, 1996) . The inactive cyclin/cdk complexes are dephosphorylated and activated by dual speci®city cdc25 phosphatases, which are, therefore, regarded as important regulators of cell cycle progression (Strausfeld et al., 1991; Honda et al., 1993; Draetta and Eckstein, 1997) .
In mammalian cells, three cdc25 isoforms have been identi®ed. The dierent enzymes, named cdc25A, B and C, show distinct expression patterns and speci®city for cdk/cyclin complexes (reviewed in Draetta and Eckstein, 1997) . Being expressed predominantly in G2, both cdc25B and cdc25C have been shown to regulate entry of cells into M phase by dephosphorylating the cdc2/cyclinB complex (Lammer et al., 1998; Sadhu et al., 1990; Nagata et al., 1991; Homan et al., 1993) . However, a more recent study shows that while overexpressing cdc25B alone can cause premature mitosis, cdc25C has to be expressed concomitantly with cyclin B to be able to shorten S phase. This evidence, together with dierential subcellular localization during the cell cycle, indicates that the two proteins probably respond to dierent cell cycle checkpoints and have distinct roles in promoting M phase (Karlsson et al., 1999) .
Cdc25A has been described as a critical regulator of the G1/S phase transition. Dierent groups suggested that cdc25A promotes entry of cells into the S phase by dephosphorylating and activating cdk2/cyclinE and cdk2/cyclinA complexes, which have been identi®ed as its in vitro substrates (Homann et al., 1994; Jinno et al., 1994) . Moreover, cdk2/cyclinE and cdk2/cyclinA complexes have been shown to be prematurely activated upon ectopic expression of cdc25A (Blomberg and Homann, 1999) . However, whether cdk2 is an in vivo target of cdc25A which is directly activated by this phosphatase has not been conclusively shown (Sexl et al., 1999) . Regarding the regulation of cdc25A expression during the cell cycle, controversial reports have been published. Cdc25A was found to be transcriptionally activated at the G1/S transition following serum stimulation of quiescent ®broblasts (Jinno et al., 1994) , with the protein accumulating in late G1. However, in another report the levels of cdc25A protein were shown to be fairly constant during the cell cycle progression of HeLa cells (Homann et al., 1994) , whereas its phosphatase activity increased in S phase and remained high throughout G2 and M (Homann et al., 1994; Blomberg and Homann, 1999) . Despite the ongoing controversy about the regulation of cdc25A, undoubtedly this phosphatase plays a role as a positive regulator of cell cycle progression. Consistent with this, cell cycle arrest induced by growth-inhibitory cytokines, such as interferon alpha (INF-a) and transforming growth factor-b (TGF-b), has been shown to be accompanied by cdc25A transcriptional repression (Tiefenbrun et al., 1996; Iavarone and Massague, 1997) .
In this study we investigated the regulation of cdc25A expression upon the induction of terminal dierentiation of myeloid cells. Myeloid leukemic M1 cells can be induced to undergo dierentiation into mature macrophages and to become growth arrested in the presence of interleukin-6 (IL-6), thus providing a useful experimental system to study how the terminal dierentiation program impacts on cell cycle progression and the proteins that regulate it. Prior to this study, we have shown that deregulated expression of cmyc blocks IL-6 induced terminal dierentiation of M1 cells, giving rise to cells which are blocked at an intermediate stage of dierentiation and continue to proliferate (Homan-Liebermann and Liebermann, 1991a) . The ®nding that cdc25A is an oncogene (Galaktionov et al., 1995; Parsons, 1998) as well as a c-myc target gene (Galaktionov et al., 1996) , prompted us to study its expression in terminally dierentiating cells to assess whether cdc25A may mediate the c-myc induced block in M1 terminal dierentiation. To accomplish this, M1cdc25A cell lines with deregulated cdc25A expression were established.
As previously shown, following 3 days treatment with IL-6, the proliferation rate of M1 cells is greatly retarded, c-myc is down-regulated and the majority of cells undergo terminal dierentiation into mature macrophages (Homan-Liebermann and Liebermann, 1991a) . In contrast, IL-6 treated M1myc cells, expressing deregulated c-myc, continue to proliferate and are blocked at an intermediate stage of macrophage dierentiation (Homan-Liebermann and Liebermann, 1991a). M1 cell dierentiation was associated with down-regulation of the mRNA and protein of both c-myc and cdc25A (Figure 1a,b; Selvakumaran et al., 1993) , whereas in IL-6-treated M1myc cells, cdc25A expression was not down-regulated ( Figure  1a ,b). These observations are consistent with the reported identi®cation of cdc25A as a myc target gene (Galaktionov et al., 1996) . However, the kinetics of expression of cdc25A and c-myc transcripts suggest that cdc25A transcription is not regulated solely by cmyc; consistent with this suggestion is the recent report that E2F also regulates the transcription of cdc25A (Vigo et al., 1999) . The observation that cdc25A continued to be expressed in M1myc cells, prompted us to investigate whether cdc25A mediates the c-mycblock in M1 terminal dierentiation. M1cdc25A cell lines expressing a cdc25A transgene were established and treated with IL-6. Surprisingly, in spite of the high level of constitutive cdc25A mRNA in the M1cdc25A cell lines, cdc25A protein was observed to be downregulated following treatment of the cells with IL-6 (Figure 1c ). Consistent with this ®nding, IL-6 induced M1cdc25A cells to undergo terminal dierentiation and growth arrest, similar to what was observed in parental M1 cells (data not shown). Taken together, these observations demonstrated that during IL-6 induced M1 terminal dierentiation, down-regulation of cdc25A expression is subject to regulation at the level of both mRNA and protein expression. In addition, the data show that deregulation of c-myc, which blocks terminal dierentiation also blocks down-regulation of cdc25A expression.
Down-regulation of cdc25A protein in M1cdc25A cells treated with IL-6, when cdc25A mRNA is constitutively expressed, unmasked a regulatory pathway that participates in the control of cdc25A protein levels during terminal dierentiation. To investigate if the down-regulation of cdc25A protein upon induction of terminal dierentiation is regulated by the ubiquitinproteasome pathway, we examined the eect of lactacystin [a potent and speci®c inhibitor of the 20S subunit of the 26S proteasome (Fenteany et al., 1995; Dick et al., 1997) ] on cdc25A levels in M1, M1myc and M1cdc25A cells, untreated or treated with IL-6. Cdc25A protein levels were analysed in the three cell lines following 48 h treatment with IL-6, followed by an additional 12 h incubation with both IL-6 and lactacystin (longer incubation with lactacystin was found to be toxic). Calpain inhibitor II, a protease inhibitor that does not inhibit the proteasome, and the solvent DMSO were used as controls.
In both M1 and M1cdc25A cells induced to dierentiate with IL-6, lactacystin increased the amount of cdc25A protein at least fourfold relative to without lactacystin (Figure 2a ), whereas neither calpain inhibitor II nor DMSO had any eect. Notably, lactacystin also elevated the level of cdc25A protein ®vefold in IL-6-treated M1myc cells, where the protein continued to be expressed ( Figure 2a ). This observation prompted us to examine the eect of lactacystin on M1, M1myc and M1cdc25A cells in the absence of IL-6, when the cells are cycling. Also under these conditions lactacystin was observed to upregulate the levels of cdc25A protein 2 ± 4-fold ( Figure  2b ). These observations, each of which was repeated at least ®ve times, indicate that cdc25A protein levels are subject to control by the ubiquitin-proteasome pathway in both cycling and dierentiating cells.
Stabilization of cdc25A by proteasome inhibitors is either indicative of direct degradation of cdc25A by the proteasome or, alternatively, it re¯ects an indirect mechanism where the protein(s) responsible for cdc25A regulation are themselves regulated by the proteasome. To determine whether cdc25A is a direct target for ubiquitination and degradation by the proteasome, a well established in vivo system was used. The human lung cancer cell line H1299 was cotransfected with expression vectors coding for cdc25A and HA-tagged-ubiquitin, and the cell extracts were analysed to identify cdc25A-ubiquitin conjugates. Following cdc25A immunoprecipitation, proteins were resolved on PAGE gels and blotted. The HA antibody used to probe Western blots recognized high molecular weight complexes only when both cdc25A and HA-ubiquitin were cotransfected (Figure 3a) . Treatment with lactacystin caused an increase in cdc25A; this can be visualized for the high molecular weight cdc25A-ubiquitin conjugates (Figure 3a) , as well as by probing Western blots with anti-cdc25A antibodies (Figure 3b ). These results are consistent with the notion that cdc25A stabilization by lactacystin in M1 cells is due to inhibition of its degradation by the ubiquitinproteasome machinery. There were no detectable high molecular weight conjugates containing HAubiquitin in cdc25A immunoprecipitates, when cells were transfected only with HA-ubiquitin and treated with lactacystin. This result demonstrated that endogenous cdc25A did not provide sucient template for detectable ubiquitin conjugation in this system, and that no ubiquitinated contaminants were coimmunoprecipitated along with cdc25A. Taken together, these ®ndings clearly demonstrate that cdc25A itself is subject to ubiquitination and degradation by the proteasome.
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To demonstrate the presence of cdc25A-ubiquitin conjugates in M1 cells, protein extracts were analysed using M1 cells treated with IL-6, IL-6 plus lactacystin or untreated. Following immunoprecipation with cdc25A antibody, duplicate Western blots were probed with either cdc25A antibody or antibody speci®c for ubiquitin. As shown in Figure 3c , high molecular weight cdc25A-ubiquitin complexes were recognized by the ubiquitin antibody. The increased level of cdc25A-ubiquitin conjugates observed following treatment of M1 cells with IL-6 is consistent with the notion that there is enhanced cdc25A degradation (M2cdc25A) were treated with 100 ng/ml IL-6 (a generous gift from Amgen Inc., Thousand Oaks, CA, USA) and analysed for c-myc and cdc25A mRNA and cdc25A protein expression. (a) 10 mgs of total RNA (equal amount of RNA was con®rmed by ethidium bromide staining of ribosomal bands) was isolated from M1 and M1myc cells treated with IL-6 for indicated times, electrophoresed on agarose formaldehyde gels and probed with 32 P-labeled c-myc cDNA, stripped and reprobed with 32 P-labeled cdc25A cDNA. Both the endogenous and exogenous RNA species of c-myc are indicated. (b) M1 and M1myc cells treated with IL-6 for 0, 2 and 3 days were harvested and lysed in RIPA buer. 250 mg of the total extract was immunoprecipitated using a polyclonal cdc25A antibody (Upstate Biotechnologies, Lake Placid, NY, USA). The Western blot was probed with the same antibody used for immunoprecipitation. A single band of *66 kDa, corresponding to cdc25A, and the immunoglobulin band are visible. IP-westerns were necessary to analyse cdc25A levels in our system because the antibody used was unable to detect this protein in a direct Western blot. (c) Cdc25A RNA and protein expression and c-myc RNA expression were analysed in IL-6-treated M1cdc25A cells as in a and b. In M1cdc25A cells, the endogenous cdc25A transcript co-migrates with the lower molecular weight exogenous transcript and, therefore, cannot be detected during dierentiation via the ubiquitin proteasome pathway.
The studies described so far, indicated that cdc25A protein levels are controlled by the ubiquitin-proteasome pathway both during cell cycle progression and terminal dierentiation. To further dissect the regulation of cdc25A protein by the ubiquitin-proteasome pathway in cycling as opposed to terminally dierentiating cells, we ®rst analysed the regulation of cdc25A protein during cell cycle progression by synchronizing M1 cells. M1 cells were treated with nocodazole or hydroxyurea to force accumulation of the cells either at mitosis (M) or at the G1/S boundary, respectively. At dierent times after release from the block in either the M or G1/S phases of the cell cycle, cells were harvested and aliquots were analysed for cell cycle distribution by¯ow cytometry and expression of cyclin B1 and cdc25A. Figure 4 shows that after nocodazole treatment, when more than 80% of the cells accumulated at mitosis [veri®ed by analysis of DNA content and quantitation of mitotic cells after Hoechst staining (data not shown)], cdc25A was expressed at levels similar to what was observed in unsynchronized control cells. The protein was maintained at the same level as the cells entered the G1 phase, and accumulated slightly as the cells were transiting through mid to late G1. The amount of cdc25A decreased and then accumulated to higher levels, as cells proceeded to the S phase. Treatment with lactacystin stabilized cdc25A throughout G1 (Figure 4 ) without changing the cell cycle distribution (data not shown). Further analysis of cdc25A expression following nocodazole treatment was not possible because the cells did not progress synchronously after 12 h. Therefore, to analyse cdc25A expression at the S/ G2 transition, M1 cells were treated with hydroxyurea, which inhibited DNA synthesis and forced the cells to be partially synchronized in G1 (about 60%), as veri®ed by FACS analysis. A synchronous transition of these cells to S and G2 at 4 and 8 h was accompanied by marked accumulation of cdc25A. It became evident, therefore, that the accumulation of cdc25A in late S, as observed with nocodazole, was maintained also as the cells progressed into G2. The expression pro®le for cyclin B1 is consistent with the cell cycle distribution. It is important to point out that steady state levels of cdc25A mRNA remained constant during this experiment (data not shown). Taken together, these observations indicated that during cell cycle progression cdc25A protein levels followed bimodal kinetics, where cdc25A accumulated in mid-late G1, followed by a decrease and a second higher accumulation at the end of S that continued into the G2 phase of the cell cycle. Con®rmation and extension of these ®ndings to non-hematopoietic cells was accomplished by analysis of cdc25A protein levels in Rat1 cells synchronized at the G0/G1 boundary by serum starvation (data not shown). Moreover, similar regulation of cdc25A also was observed in H1299 cells transiently transfected with a cdc25A expression vector and synchronized with nocodazole and hydroxyurea (data not shown). In this experiment it was possible to visualize cdc25A in a direct Western blot due to overexpression of cdc25A by transient transfection.
Important information on the regulation of cdc25A upon induction of terminal dierentiation was obtained by analysis of the cell cycle distribution of M1 and M1cdc25A cells at dierent times following treatment (Table 1) . After treatment of M1 and M1cdc25A cells with IL-6 for 3 days, a point in time when cdc25A protein was completely degraded ( Figure  1b,c) , about 30% of the cells were in the S or G2/M phases of the cell cycle. It should be kept in mind that in cycling cells cdc25A protein accumulates to its highest levels in late S and G2 phases of the cell cycle ( Figure 4) ; therefore, the complete degradation of cdc25A protein by 3 days following treatment of cells with IL-6 cannot be accounted for by redistribution of the cells in the cell cycle, but rather by degradation occurring throughout the cell cycle.
To compare cdc25A stability in cycling versus terminally dierentiating cells, we analysed degradation rates. M1, M1myc and M1cdc25A cells, either untreated or treated with IL-6 for 48 h, were incubated with cycloheximide to block new protein synthesis; the cells were collected at dierent times to ascertain cdc25A protein levels. A representative experiment is shown in Figure 5a for M1 and M1myc cells. Quanti®cation of cdc25A levels from three independent experiments and calculation of the half-life (Figure 5b ), clearly demonstrated that the half-life of cdc25A protein was signi®cantly shorter in M1 cells induced for terminal dierentiation by IL-6 (less than 25 min) compared to cycling M1 cells (70 min). The half-life of cdc25A in M1cdc25A cells was very similar to M1 cells (data not shown). These ®ndings demonstrate that the degradation of cdc25A in dierentiating cells is more rapid than in control, cycling cells, and is likely to occur in all phases of the cell cycle. In M1myc cells the half life of cdc25A protein was greater than 90 min and remained the same following treatment with IL-6, thereby demonstrating that deregulated c-myc expression not only blocked terminal dierentiation but also blocked IL-6 induced degradation of cdc25A.
In this work we demonstrate, for the ®rst time, that expression of cdc25A protein is subject to regulation by the ubiquitin-proteasome pathway, in both cycling and terminally dierentiating cells. Evidence is presented that the rate of cdc25A degradation by the ubiquitinproteasome machinery during terminal dierentiation is accelerated compared to its rate of degradation in cycling cells. Moreover, the complete degradation of cdc25A upon induction of dierentiation is likely to take place in all phases of the cell cycle.
Our results have also demonstrated that cdc25A protein levels display bimodal kinetics of expression in cycling cells, with a peak of accumulation in mid-late G1 and maximal expression in late S, persisting into the G2 phase of the cell cycle. The generality of these ®ndings is inferred by the fact that similar results were obtained in both M1 myeloid cells and in Rat1 ®broblasts. Our ®nding that cdc25A protein accumulates in late G1 is consistent with what was previously observed upon serum stimulation of quiescent NRK ®broblasts (Jinno et al., 1994) . The ®nding of a second higher peak of cdc25A accumulation in late S through G2 is novel. It is important to point out that, although cdc25A protein levels were reported not to vary considerably in cycling HeLa cells (Homann et al., 1994) , a slight increase at the beginning of G2 was apparent, consistent with cdc25A activity increasing in S and G2 phases (Homann et al., 1994) . More recently, further evidence was obtained that cdc25A activity is increased in S and G2 phases of the cell cycle Figure 3 Ubiquitination of cdc25A. (a and b) H1299 cells were transiently transfected with lipofectamine (GIBCO ± BRL, Gaithersburg, MD, USA), according to the manufacturer's instructions, with a total of 6 mg of DNA consisting of 2 mg of cdc25A expression vector, 3 mg of HA-ubiquitin expression vector (obtained from Dr Dirk Bohman), and 1 mg b-galactosidase vector per 100 mm dish. After 8 h, the transfection medium was replaced with fresh medium and expression was allowed to proceed for 24 h. Where indicated, lactacystin was added to the culture for the last 12 h. All cell extracts were normalized for transfection eciency by measuring b-galactosidase activity expression. (a) Extracts were immunoprecipitated with cdc25A antibody (NeoMarkers, Fremont, CA, USA) and immunoblotted with anti-HA antibody (Roche Molecular Biochemicals, Indianapolis, IN, USA). Since the cdc25A antibody used in this experiment was a mixture of two monoclonal antibodies, the band corresponding to the Ig is a doublet. The band above the Ig is non speci®c. (b) Cell extracts were analysed by immunoblotting, using cdc25A antibody. Equal loading was veri®ed by Ponceau staining (not shown). (c) Cell extracts from M1 cells, untreated (lane 1), treated with IL-6 for 24 h (lane 2) and treated with IL-6 for 24 h with the addition of lactacystin for the last 12 h (lane 3) were immunoprecipitated and duplicate Western blots were probed with either cdc25A antibody or ubiquitin antibody to detect cdc25A-ubiquitin complexes. The commercial anti-cdc25A antibodies used in our experiments did not detect cdc25A-ubiquitin conjugates, in either M1 or H1299 cells. One possible explanation is that the epitopes recognized by the antibodies were masked by ubiquitin, or, alternatively, the sensitivity of the antibodies was not sucient to detect the lower concentrations of cdc25A protein associated with ubiquitin (Sexl et al., 1999; Blomberg and Homann, 1999) , although in some cell types there is a decrease in cdc25A protein expression (Blomberg and Homann, 1999) . The bimodal expression kinetics of cdc25A protein is consistent with a role for cdc25A in the G1/S transition and also later in the cell cycle. In support of this hypothesis cdc25A was shown to be a critical regulator of G1-S progression in cells that were serum starved and arrested in G0 (Homann et al., 1994; Jinno et al., 1994; Blomberg and Homann, 1999) . Furthermore, when anti-cdc25A antibodies were microinjected into asynchronous cells, inhibition of cdc25A activity caused an M-phase arrest (Galaktionov and Beach, 1991) .
Cdc25A levels during the cell cycle are likely to be regulated by a complex and delicate balance between its synthesis and degradation rates. Degradation mediated by the proteasome certainly plays an important role, since the proteasome inhibitor lactacystin was able to eliminate the¯uctuations in cdc25A as cells progressed from G1 to S. Nonetheless, we have not investigated whether there was also a dierence in the synthesis rate of cdc25A protein during the cell cycle; therefore, the accumulation of cdc25A in S/G2 could be due to either increased rate of synthesis or decreased rate of degradation, or both.
It had been previously reported that yeast cdc25 and human cdc25B are regulated by the ubiquitin-proteasome pathway (Nefsky and Beach, 1996; Baldin et al., 1997) . The ®nding that cdc25A is also subject to regulation by the ubiquitin-proteasome machinery extends the involvement of this pathway to yet another family member. Furthermore, we have observed that cdc25A degradation by the proteasome diers in terminally dierentiating versus cycling cells. This raises the possibility that dierent ubiquitin-proteasome pathways operate to degrade cdc25A during cell cycle progression and terminal dierentiation. It is well established that ubiquitination of proteins is a multienzymatic process (Hochstrasser, 1996) , and E3 proteins appear to be the primary substrate recognition factors (Hershko and Ciechanover, 1992) . In most cases, the multi-ubiquitination of proteins is a regulated event and the speci®city of it is achieved either through post-translational modi®cation of the target protein, such as by phosphorylation, or through Figure 4 Cdc25A protein levels during cell cycle progression of M1 cells. M1 cells were synchronized in either the M or G1 phase by incubation with either 50 ng/ml nocodazole or 1.5 mM hydroxyurea, respectively. After 14 h incubation, cells were washed and replated in fresh medium. Cells were harvested after dierent periods of time and the cell cycle stage was monitored by¯ow cytometry using a Coulter Epics Elite system (Miami, FL, USA). Cyclin B1 protein levels were assessed by immunoblotting (Santa Cruz, GNS1 using 40 mg cell extracts), and cdc25A protein level was assessed by IP-Western blotting. The graph depicts the percentage of cells in the dierent phases of the cell cycle at dierent times after release from the block. Expression of cyclin B1 is consistent with the¯ow cytometry data. Where indicated, upon release from nocodazole treatment, M1 cells were incubated with 1 mM lactacystin for 3, 6 or 9 h. The cell cycle distribution of these cells is not reported since it was similar to cells without lactacystin. The data shown here are representative of three independent experiments that yielded similar results the action of regulated E3 ubiquitin-ligases that recognize speci®c motifs in target proteins (for comprehensive reviews, see Ciechanover, 1994 Ciechanover, , 1998 Laney and Hochstrasser, 1999) . Current work is aimed at identifying dierences in speci®c E3 ligase(s) and/or post-translational modi®cations of cdc25A prior to its degradation in cycling versus terminally dierentiating cells. The expression of many important regulators of the cell cycle has been shown to be regulated by the ubiquitin-proteasome pathway (reviewed in King et al., 1996; Hershko, 1997; Hoyt, 1997) . Some of these proteins, such as cyclin D1 and p21, also have been shown to be regulated by the ubiquitin-proteasome pathway upon the induction of terminal dierentiation (Spinella et al., 1999; Di Cunto et al., 1998) . Our results add further evidence to a model in which cell cycle arrest during terminal dierentiation is achieved through tight transcriptional and post-translational control of cell cycle proteins.
To better understand how cdc25A protein stability is regulated under dierent physiological conditions, it can be asked if this protein is also destabilized in response to growth inhibition, in the absence of dierentiation. Cdc25A expression was found to be down-regulated by several growth inhibitory cytokines, including INF-a and TGF-b, where it was observed to be at the transcriptional level (Tiefenbrun et al., 1996; Iavarone and Massague, 1997) . Ascertaining how cdc25A protein stability is regulated in response to these growth inhibitory cytokines would give additional insights into understanding the regulation of growth arrest (Homan-Liebermann and Liebermann, 1991b; Selvakumaran et al., 1994) .
Finally, we have observed that deregulated expression of c-myc, which blocked terminal dierentiation, also blocked IL-6 induced degradation of cdc25A by the ubiquitin-proteasome machinery. Exactly how cmyc exerts its inhibitory eect on IL-6 induced degradation of cdc25A is an interesting question that will be the subject of future studies. That cdc25A protein continues to be expressed in M1myc cells following induction of dierentiation led us to ask whether a stable form of cdc25A can mimic the c-myc mediated block in M1 terminal dierentiation. To determine this, cdc25A mutants are being engineered to prevent down-regulation of the protein in dierentiating M1 cells.
Cdc25A is an oncogene (reviewed in Parsons, 1998) whose expression was found to be elevated in colon cancers (Dixon et al., 1998) . A better understanding of cdc25A regulation by the ubiquitin-proteasome pathway and characterization of regions within cdc25A which dictate its destruction, should provide better insights into elucidating the oncogenic properties of this protein.
